TD Cowen Highlights a 'Compelling 2026-2028 Margin Story' at DexCom (DXCM)

TD Cowen analyst Joshua Jennings reiterated a Buy rating and $84.00 price target on DexCom (NASDAQ: DXCM).

The analyst commented: "Raising Estimates To Reflect DXCM's Compelling 2026-2028 Margin Story; Given recent concerns around a slowing of the US CGM market (law of large numbers) following DXCM/ABT's 2026 guidance releases, we believe profitability improvements may become top of mind for DXCM investors. We still believe in the US reacceleration following Medicare T2NIT access expansion, but for now, we identify an extremely compelling case for 2026-2028 gross and operating margin expansion."

For an analyst ratings summary and ratings history on DexCom click here. For more ratings news on DexCom click here.

Shares of DexCom closed at $62.37 yesterday.

You May Also Be Interested In

• Micron Technology (MU) PT Raised to $1,550 at Needham
• Dutch Bros Inc. (BROS) PT Raised to $68 at Piper Sandler
• H.C. Wainwright Reiterates Buy Rating on Zymeworks (ZYME)